Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01303341
Title Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Riluzole + Sorafenib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.